Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Grants Priority Review for Daiichi Sankyo's NDA for FLT3 Inhibitor Quizartinib

americanpharmaceuticalreviewNovember 29, 2018

Tag: FDA , Daiichi Sankyo , Quizartinib , NDA

PharmaSources Customer Service